Group 1: Event Overview - The investor relations activity took place from February 26 to March 26, 2026 [2] - The event was held at the New Industry Biomedical Building, located at 23 Jinxiu East Road, Jinsha Community, Pingshan District, Shenzhen [2] - A total of 29 institutions and 37 participants attended the event [2] Group 2: Participants - Notable participants included major asset management firms such as Fidelity Investments, T. Rowe Price Associates, and J.P. Morgan Investment Management [3] - The complete list of participating institutions is available in the attached document [4] Group 3: Company Representatives - The event featured company representatives including Zhang Lei, the Deputy General Manager and Secretary of the Board, and Lü Yuning, the Head of Investor Relations [2] - No new major interactive content was introduced beyond previously disclosed investor relations activities [2]

Core Viewpoint - Researchers have developed an electronic implant system that can monitor and influence the maturation process of human islet cells, providing a key technological platform for constructing functionally mature human islets and offering new insights for cell-based diabetes therapies [3][4]. Group 1: Technology Development - The electronic implant system integrates a thin conductive mesh structure into growing pancreatic tissue, allowing for the recording of electrical signals produced by islet cells and the application of precise electrical stimulation to influence their development [3][5]. - This system is described as "bionic" or "cyber-organ," combining electronic systems with living tissues to create a controllable biological system [3]. Group 2: Application in Diabetes Treatment - In Type 1 diabetes, the immune system attacks islet cells, leading to a loss of insulin secretion capability. Laboratory-cultured functional pancreatic tissue is seen as a potential alternative to donor pancreas or islet transplants, which are limited by donor availability and require long-term immunosuppressive therapy [4]. - The research team implanted a stretchable electronic mesh within developing three-dimensional pancreatic organoids, enabling the recording of electrical activity from individual islet cells for up to two months and observing their maturation process [5]. Group 3: Findings and Future Applications - The introduction of a 24-hour electrical activity cycle similar to the human biological clock resulted in islet cells maintaining this rhythmic activity and hormone secretion at appropriate times after several days of rhythmic stimulation [5]. - This technology may have two potential applications: training laboratory-cultured islet cells through electrical stimulation before transplantation, or retaining the electronic mesh post-transplantation for continuous monitoring and stimulation to prevent functional decline under stress or disease [5].

Core Insights - The National Natural Science Foundation of China has officially released the 2026 project guidelines, establishing an independent discipline for "Organoids and Artificial Organs" under the life sciences sector C10, with application code C1004 [1][2]. Group 1: New Discipline Establishment - The addition of the independent discipline code marks a strategic focus on organoid and organ-on-chip research, highlighting its importance in national basic research [2][11]. - This initiative follows the earlier establishment of the "Organ-on-Chip and Systems" independent discipline under H28 "Biomedical Engineering / Regenerative Medicine" in 2025, with application code H2812 [2][11]. Group 2: Research and Evaluation Enhancements - The new code provides a dedicated platform for academic exchange and resource support, allowing researchers to focus on core areas of organoid and organ-on-chip development without the constraints of other disciplines [4][16]. - The evaluation system will become more specialized, enabling peer review to concentrate on the unique scientific logic of organoid research, thus allowing innovative studies to stand out [4][16]. Group 3: Strategic Importance - This adjustment signifies the national recognition of the core value of organoid and organ-on-chip technologies, enhancing their strategic position in the national research framework [6][19]. - The establishment of this independent category is expected to attract more research talent to the field, fostering interdisciplinary innovation and accelerating the application of technological results [10][19].

Core Viewpoint - The establishment of an independent discipline for "Organoids and Artificial Organs" under the National Natural Science Foundation's 2026 project guidelines signifies a strategic focus on this cutting-edge field, presenting unprecedented development opportunities [2][9]. Group 1: New Discipline Establishment - The new application code C1004 for "Organoids and Artificial Organs" has been introduced, marking a significant addition to the C10 discipline system of "Biomaterials, Imaging, and Tissue Engineering" [2][6]. - This initiative follows the earlier introduction of the independent discipline "Organ-on-a-Chip and Systems" under the H28 biomedical engineering category in 2025, indicating a growing emphasis on organoid and organ-on-a-chip research [2][6]. Group 2: Research Focus and Evaluation - The establishment of a dedicated code allows researchers to focus on core issues in the organoid field without the constraints of aligning with other disciplines, enhancing the depth of exploration in areas such as disease simulation models and drug screening [8][9]. - The new evaluation system is designed to better assess the unique scientific logic of organoid research, enabling innovative studies to stand out and receive appropriate recognition [7]. Group 3: Strategic Importance - This adjustment reflects the national recognition of the core value of organoid and organ-on-a-chip technologies, positioning them as key elements in overcoming bottlenecks in biomedical research and enhancing international competitiveness [9]. - The initiative aims to attract more research talent to the field, fostering interdisciplinary innovation and accelerating the application of technological advancements [9].

Core Viewpoint - A collaborative effort among several institutions has led to the development of a flexible bioelectronic patch that allows for precise and controlled drug delivery directly to affected organs, addressing limitations of traditional drug administration methods [1][3]. Group 1: Technology and Innovation - The bioelectronic patch, likened to a "smart electronic garment," can conform to irregularly shaped organs such as the kidneys and ovaries, enabling targeted drug delivery [1][3]. - The research team utilized a combination of engineering and medical sciences to create a patch made of numerous modular units that fit specific organ curvatures, overcoming previous limitations of patches that could only be used on smooth organ surfaces [3]. - The patch features a three-dimensional structure with "nano-pores, micro-channels, and micro-electrodes," allowing for controlled electrical currents that temporarily open cell membranes, facilitating drug entry into target cells [3][4]. Group 2: Clinical Applications - Traditional drug delivery methods can harm healthy cells, particularly in sensitive organs; the bioelectronic patch aims to minimize this risk by delivering drugs directly to the organ without affecting the entire immune system [4]. - The patch has potential applications in treating conditions such as diabetes, retinal diseases, and rheumatoid arthritis, offering personalized and minimally invasive medical solutions for patients [5].

Core Viewpoint - The article highlights the advancements in non-invasive brain-machine interface (BMI) technology developed by the Suzhou Institute of Biomedical Engineering and Technology, emphasizing the integration of scientific research and industrial application to address clinical needs and enhance patient care [1][6]. Group 1: Technology Development - The Suzhou Institute has developed a non-invasive BMI technology that allows for real-time imaging of blood flow in capillaries within the brain, showcasing its potential for various applications [1]. - A novel temperature-controlled phase-change conductive gel based on natural gelatin has been created, which significantly improves the comfort and usability of the electrodes by eliminating the need for shaving hair and enhancing signal quality by over 100 times compared to traditional electrodes [2]. - The research team is working on overcoming the challenge of deep imaging through advancements in ultrasound and optical imaging technologies, aiming to capture brain activity with high precision [3]. Group 2: Clinical Application and Innovation - The integration of ultrasound imaging technology has enabled the team to visualize microvascular flow in the brain, which is crucial for understanding neural activity, with plans to develop specialized equipment for research applications [3]. - A new wireless wearable EEG system has been developed that can decode patients' intentions during imagined movements, aiding in rehabilitation for stroke patients and other neurological conditions [4]. - The team is also involved in establishing the first national standards for wearable BMIs, which is expected to enhance product quality and promote sustainable development in the BMI industry [5]. Group 3: Collaborative Efforts and Future Directions - The collaborative efforts of multiple research teams at the Suzhou Institute illustrate a clear path for integrating technological innovation with industrial application, focusing on real-world needs and interdisciplinary cooperation [6]. - The establishment of standards and regulations in the BMI sector is seen as a critical step towards maturing the technology and facilitating its transition into practical use, thereby unlocking its economic value [5][6].

Group 1: Event Overview - The investor relations activity involved 36 institutions with a total of 50 participants [2] - The event took place from December 2 to December 31, 2025 [2] - The location was at the New Industry Biomedical Building, No. 23, Jinxiu East Road, Kengzi Street, Pingshan District, Shenzhen [2] Group 2: Participants and Representatives - Key representatives from the company included Chairman and General Manager Rao Wei, Deputy General Manager and Board Secretary Zhang Lei, and Investor Relations Head Lv Yuning [2] - The list of participating institutions includes notable firms such as Fidelity International Ltd., HSBC Asset Management, and several others [3] Group 3: Activity Content - The main content of the investor relations activity did not introduce any new major interactive communication beyond previously disclosed information [2]

Core Viewpoint - The article discusses a new strategy in dynamic tissue engineering (DTE) for tracheal reconstruction, highlighting the continuous regulatory role of biomaterials in cell behavior and tissue evolution during the regeneration process [3]. Group 1: Research Findings - The research team developed a bio-adaptive physical hydrogel (BP-Gel) based on PLGA-PEG-PLGA, which allows for dynamic adjustment of the physical cross-linking network in response to cell migration, aggregation, and rearrangement [6]. - The study found that in this environment, chondrocytes are not fixed in predetermined positions but undergo spontaneous spatial reorganization, gradually forming a hierarchical cartilage structure with developmental characteristics, significantly enhancing the mechanical stability and degradation resistance of engineered cartilage [6]. Group 2: Immune Modulation and Functional Characteristics - BP-Gel also serves as a delivery platform for the sequential release of immune-modulating factors. By incorporating a gel system loaded with IL-4/IL-13, the research team shaped a pro-repair immune microenvironment in the early stages of regeneration, promoting angiogenesis and accelerating airway epithelial maturation without interfering with cartilage phenotype [9]. - In in vivo models, tracheal substitutes constructed using the dynamic tissue engineering strategy exhibited functional characteristics closer to natural trachea in terms of long-term ventilation maintenance, cartilage retention, and vascular and epithelial reconstruction [9]. Group 3: Implications for Future Research - Overall, the study reveals that the dynamic synergy between materials, cells, and microenvironments is a key mechanism for achieving complex tracheal regeneration, providing new theoretical foundations and potential translational directions for airway reconstruction and other composite tissue engineering [9].

Group 1: Event Overview - The investor relations activity took place from November 3 to November 27, 2025 [2] - The event was held at the New Industry Biomedical Engineering Building, located at 23 Jinxiu East Road, Kengzi Street, Pingshan District, Shenzhen [2] - A total of 60 institutions participated, with 92 attendees [2] Group 2: Participants and Activities - The event included various formats such as on-site visits, online communications, and strategy meetings with major financial institutions [2] - Notable participating institutions included Abu Dhabi Investment Authority, Credit Suisse, and J.P. Morgan Asset Management [5][6] Group 3: Company Representatives - The event was attended by Zhang Lei, the Deputy General Manager and Secretary of the Board, and Lü Yuning, the Head of Investor Relations [2] - No new major communication content was introduced beyond previously disclosed investor relations activities [2]

Core Viewpoint - A novel non-invasive method for brain stimulation using microelectrodes delivered via immune cells has been developed, potentially revolutionizing the treatment of neurological diseases without the need for invasive surgery [1][2][3]. Group 1: Research Background - Traditional treatments for brain diseases like Parkinson's and epilepsy often require invasive electrode implantation through craniotomy, which carries risks of infection and tissue damage [1]. - Existing non-invasive techniques, such as transcranial magnetic stimulation, lack the spatial resolution needed for precise neuronal control [1]. Group 2: Innovative Technology - The research team introduced a biological "delivery" system named "Circulatronics," utilizing subcellular-sized wireless electronic devices (SWEDs) that are approximately 10 micrometers in diameter [2]. - These devices can be powered wirelessly by near-infrared light, which penetrates several centimeters of tissue, including the skull and brain [2]. Group 3: Experimental Validation - In experiments, the team induced localized inflammation in the brains of mice and injected the "cell-electronic" hybrids, which successfully targeted the inflamed areas [3]. - The devices were activated by external near-infrared light, demonstrating precise stimulation of surrounding neurons with a spatial accuracy of 30 micrometers [3]. Group 4: Future Implications - The technology could potentially eliminate the need for craniotomy in treating various inflammation-related neurological diseases, such as Alzheimer's and post-stroke conditions [3]. - There is potential for broader applications by using different types of immune cells for targeting other diseases in various body parts [3]. Group 5: Current Limitations - The technology is still in early animal testing stages, and improvements in targeting efficiency and long-term safety need to be validated through larger studies [4].